Home › Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration
 

Keywords :   


Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration

2014-02-05 07:17:03| drugdiscoveryonline News Articles

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, recently announced that it has elected to retain the United States development and commercial rights to the isocitratedehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism

Tags: rights under development program

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
01.07Atlantic Tropical Weather Outlook
01.07Hurricane Beryl Graphics
01.07Hurricane Beryl Public Advisory Number 9A
01.07Summary for Hurricane Beryl (AT2/AL022024)
01.07Tropical Depression Three Graphics
01.07Tropical Depression Three Public Advisory Number 1A
01.07Summary for Tropical Depression Three (AT3/AL032024)
01.07Eastern North Pacific Tropical Weather Outlook
More »